Emergent BioSolutions Secures US FDA Approval Of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), Previously Known As AV7909, A Two-Dose Anthrax Vaccine For Post-Exposure Prophylaxis Use
Portfolio Pulse from Benzinga Newsdesk
Emergent BioSolutions has received US FDA approval for CYFENDUS, a two-dose anthrax vaccine for post-exposure prophylaxis use. The company has been delivering the vaccine to the U.S. Department of Health and Human Services since 2019 under pre-Emergency Use Authorization status.
July 20, 2023 | 10:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Emergent BioSolutions' FDA approval for CYFENDUS could potentially increase the company's revenues as it transitions to post-approval procurement.
The FDA approval of CYFENDUS allows Emergent BioSolutions to transition from pre-Emergency Use Authorization status to post-approval procurement. This could potentially increase the company's revenues as it can now sell the vaccine on a larger scale.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100